Arcutis Announces Third Quarter 2026 Financial Results and Provides Business Update
Higher sales supported quarterly profitability and positive operating cash flow, while marketing and personnel spending increased.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Arcutis Biotherapeutics (Nasdaq: ARQT) reported third-quarter 2026 ZORYVE net product sales of $143.9 million, reflecting growth across its products. Sales rose 45% year over year and 11% sequentially, primarily on increased unit demand. Net income reached $8.8 million versus $7.4 million a year earlier; diluted earnings per share remained $0.06. Operating activities generated $18.9 million in cash.
The company raised its 2026 net product sales outlook to $535 million–$545 million from $525 million–$540 million. Selling, general and administrative expenses increased to $99.6 million from $62.4 million. Arcutis initiated a Phase 3 trial in moderate to severe atopic dermatitis and expects vitiligo results and an advancement decision by year-end. The FDA set February 23, 2027, as its target action date for expanding ZORYVE cream 0.05% use to infants aged 3 to 24 months.
How this balance works
Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.
It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.
Rhea-AI Sentiment measures something else, the tone of the wording.
Hollow bars mark forward-looking points. How the balance works
Positive
- Major point. Forward-looking: it has not happened yet and may not happen.Arcutis raised 2026 sales guidance to $535 million–$545 million from $525 million–$540 million.
- Moderate pointQ3 ZORYVE sales of $143.9 million rose 45% year over year and 11% sequentially.
- Moderate pointPhase 3 trial initiated for ZORYVE cream 0.3% in adults and children with moderate to severe atopic dermatitis.
- Minor pointQ3 net income increased to $8.8 million from $7.4 million; diluted EPS remained $0.06.
- Minor pointQ3 operating cash flow was positive at $18.9 million.
11 minor points
- Minor pointCash, restricted cash and marketable securities reached $259.8 million versus $221.3 million at December 31, 2025.
- Minor pointQ3 operating income increased to $9.436 million from $8.526 million a year earlier.
- Minor pointNine-month net product revenue increased to $379.178 million from $244.569 million in 2025.
- Minor pointNine-month net income reached $12.515 million versus a $33.536 million loss in 2025.
- Minor point. Forward-looking: it has not happened yet and may not happen.Arcutis expects vitiligo Phase 2 results and an advancement decision by year-end 2026.
- Minor point. Forward-looking: it has not happened yet and may not happen.Arcutis expects hidradenitis suppurativa Phase 2 results and an advancement decision in Q1 2027.
- Minor pointARQ-234 Phase 1a/1b enrollment continues, with progression to the multiple ascending dose portion.
- Minor pointPhase 4 INTEGUMENT-ITCH enrollment continues, evaluating itch improvement in adults with atopic dermatitis.
- Minor point. Forward-looking: it has not happened yet and may not happen.Arcutis is preparing enrollment for a Phase 2 trial treating checkpoint inhibitor-related skin adverse events.
- Minor pointOne new U.S. patent obtained in Q4 2026 covers topical PDE4 inhibitor foam compositions.
- Minor pointQ3 interest expense decreased to $2.959 million from $3.071 million a year earlier.
Negative
- Moderate pointQ3 selling, general and administrative expenses rose to $99.6 million from $62.4 million.
- Moderate pointInfant indication expansion remains pending FDA action, with a February 23, 2027, target date.
- Minor pointQ3 research and development expenses rose to $22.4 million from $19.6 million.
- Minor pointQ3 cost of sales increased to $12.5 million from $8.7 million as ZORYVE sales volume increased.
- Minor pointNine-month interest expense increased to $10.733 million from $9.082 million in 2025.
- Minor pointCurrent long-term debt increased to $6.950 million from $1.000 million at December 31, 2025.
News Explained
In its third-quarter results, Arcutis reported cash, cash equivalents, restricted cash and marketable securities of
Details
Market Reaction – ARQT
On Nov 4, the day this news came out, the latest delayed price for ARQT is 12.39% below the previous close. Our momentum scanner has recorded 70 alerts for this stock so far that day. The latest delayed price is $29.83.
Data tracked by StockTitan Argus (15 min delayed). Upgrade to Gold for real-time data.
Key Figures
- Net product revenue
- $143.9 million
- Q3 2026
- Year-over-year revenue growth
- 45%
- Q3 2026 versus Q3 2025
- Sequential revenue growth
- 11%
- Q3 2026 versus Q2 2026
- FY 2026 net product sales guidance
- $535 million–$545 million
- Raised from $525 million–$540 million
- Net income
- $8.8 million
- Q3 2026
- Diluted earnings per share
- $0.06
- Q3 2026
- Cash provided by operating activities
- $18.9 million
- Q3 2026
- FDA target action date
- February 23, 2027
- Supplemental application for ZORYVE cream 0.05% in infants aged 3 to 24 months
Previous Earnings Reports
-
ZORYVE revenue grew, guidance was raised, and operating cash flow was positive.
-
ZORYVE revenue grew year over year and the company reported positive operating cash flow.
-
ZORYVE revenue grew and 2026 net product sales guidance was introduced.
-
ZORYVE revenue grew year over year and the company reported net income.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Key Terms
pde4 inhibitor medical
supplemental new drug application regulatory
gross-to-net financial
multiple ascending dose medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
- Continued strong ZORYVE® (roflumilast) net product revenue growth, with Q3 revenues of
$143.9 million , +45% versus Q3 of 2025, and +11% versus Q2 of 2026, driven by strong demand growth - Raised 2026 full-year net product sales guidance to
$535 million –$545 million - Partnered with World Champion gymnast Simone Biles to launch the Skin to Believe In awareness campaign for individuals living with inflammatory skin conditions
- Remains on track to disclose topline results from Phase 2 trial of ZORYVE foam
0.3% in individuals with vitiligo and decision on program advancement in Q4 of 2026 - Maintained positive operating cash flow for the quarter with
$18.9 million of net cash provided by operating activities
WESTLAKE VILLAGE, Calif., Nov. 04, 2026 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today reported financial results for the quarter ended September 30, 2026, and provided a business update.
“Yet another strong quarter of performance reflects the consistent execution of our corporate strategy and further strengthens our financial position. ZORYVE continues to lead the branded non-steroidal topical segment driven by its efficacy and tolerability across multiple inflammatory skin conditions and patient populations. We are very excited to launch a new awareness campaign with Simone Biles, a World Champion gymnast who uses ZORYVE herself, to raise awareness of inflammatory skin diseases and of advanced targeted topicals like ZORYVE,” said Frank Watanabe, president and chief executive officer. “Looking ahead, with a potential FDA approval of ZORYVE cream
Third Quarter 2026 Financial Results and Business Updates
Commercial Highlights
ZORYVE — a highly potent and selective phosphodiesterase-4 (PDE4) inhibitor in once-daily cream and foam formulations, approved in the United States and Canada for the treatment of plaque psoriasis, atopic dermatitis, and seborrheic dermatitis.
- ZORYVE net product sales for the third quarter of 2026 were
$143.9 million , reflecting45% year-over-year growth and an11% sequential increase versus the second quarter of 2026. The year-over-year and sequential increases were driven by increasing demand across products. - Launched the Skin to Believe In campaign with Simone Biles to raise awareness of seborrheic dermatitis and eczema and to encourage individuals to talk to their doctor about long-term, steroid-free, topical treatment options for their skin conditions, including ZORYVE.
Clinical and Regulatory Developments
- The Company initiated a pivotal Phase 3 trial with ZORYVE cream
0.3% for the treatment of adults and children with moderate to severe atopic dermatitis, distinct from the current indication of ZORYVE cream0.15% for the treatment of adults and children 6 years of age and older with mild to moderate atopic dermatitis. - The FDA has set a target action date of February 23, 2027, for the supplemental New Drug Application to expand the indication for ZORYVE cream
0.05% for mild to moderate atopic dermatitis to infants aged 3 to 24 months. - The Company continues to enroll patients in a Phase 4 study evaluating quality and speed of itch improvement with ZORYVE cream
0.15% in adult patients with atopic dermatitis (INTEGUMENT-ITCH). - The Company remains on track to disclose topline results from the Phase 2 proof-of-concept study of ZORYVE foam
0.3% for the treatment of vitiligo and share its decision on program advancement by the end of 2026. - The Company continues to enroll patients in the Phase 2 proof-of-concept studies of ZORYVE foam
0.3% for the treatment of hidradenitis suppurativa, and expects to report results, as well as a decision on program advancement, in the first quarter of 2027. - The Company is preparing to enroll a Phase 2 trial evaluating the safety and efficacy of ZORYVE foam
0.3% in the treatment of cutaneous adverse events due to checkpoint inhibitors. - The Company continues to enroll patients in the Phase 1a/1b study of ARQ-234, a potent and highly selective checkpoint agonist of the CD200 receptor, for the treatment of atopic dermatitis and has progressed to the multiple ascending dose portion of the trial.
Corporate Updates
- Appointed Rob Lisicki, a commercial and executive leader with over 30 years of biopharmaceutical industry experience, as chief commercial officer, effective November 4, 2026.
- Appointed Rob Scott, MD, a global pharma industry leader and pioneer, to the Board of Directors in October 2026.
- ZORYVE cream
0.15% received the 2026 "Best Prescription Skin Solution" Award from Marie Claire magazine, the first time a prescription drug has been recognized by this prestigious publication. - Sustained positive cash flow, generating
$18.9 million of cash flow from operating activities in the third quarter of 2026. - Obtained one new U.S. patent in the fourth quarter of 2026 related to topical PDE4 inhibitor foam compositions.
Third Quarter 2026 Summary Financial Results
Product revenues for the quarter ended September 30, 2026 were
Cost of sales for the quarter ended September 30, 2026 was
Research and development (R&D) expenses for the quarter ended September 30, 2026 were
Selling, general, and administrative (SG&A) expenses for the quarter ended September 30, 2026 were
Net income was
Cash, cash equivalents, restricted cash, and marketable securities were
Financial Guidance
- The Company raised net product sales guidance for the full year 2026 to
$535 million –$545 million from$525 million –$540 million .
Conference Call and Webcast
Arcutis management will host a conference call and webcast today at 4:30 p.m. ET to discuss the financial results for the quarter and provide a business update. The webcast for this conference call may be accessed at the “Events” section of the Company’s website. The replay of the webcast will be available on the Company's website following the call.
About Arcutis
Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT) is a commercial-stage medical dermatology company that champions meaningful innovation to address the urgent needs of individuals living with immune-mediated dermatological diseases and conditions. With a commitment to solving the most persistent patient challenges in dermatology, Arcutis has a growing portfolio of advanced targeted topicals approved to treat three major inflammatory skin diseases. Arcutis’ unique dermatology development platform coupled with our dermatology expertise allows us to develop differentiated therapies against biologically validated targets, and has produced a robust pipeline for a range of inflammatory dermatological conditions. For more information, visit www.arcutis.com or follow Arcutis on LinkedIn, Facebook, Instagram, and X.
Forward Looking Statements
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. For example, statements contained in this press release regarding matters that are not historical facts are forward-looking statements. These statements are based on the Company's current beliefs and expectations. Such forward-looking statements include, but are not limited to, statements regarding the potential to address large markets with significant unmet need; the progression of the development, approval, and potential commercialization of product candidates and expanded indications; the potential commercial success and growth of ZORYVE in plaque psoriasis, seborrheic dermatitis, and atopic dermatitis, including peak sales, market access and reimbursement, product demand growth and developments regarding GTN; future product sales guidance; and the timing of regulatory filings and potential approvals. These statements involve substantial known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance, or achievements to be materially different from the information expressed or implied by these forward-looking statements and you should not place undue reliance on our forward-looking statements. Risks and uncertainties that may cause our actual results to differ include risks inherent in the clinical development process and regulatory approval process, the timing of regulatory filings, the timing, expenses, and success of our commercialization efforts, including uncertainty of future commercial sales and related items that can impact net sales, and our ability to defend our intellectual property. For a further description of the risks and uncertainties applicable to our business, see the “Risk Factors” section of our Form 10-K filed with the U.S. Securities and Exchange Commission (SEC) on February 25, 2026, as well as any subsequent filings with the SEC. Any forward-looking statements that the Company makes in this press release are made pursuant to the Private Securities Litigation Reform Act of 1995, as amended, and speak only as of the date of this press release. Except as required by law, we undertake no obligation to revise or update information herein to reflect events or circumstances in the future, even if new information becomes available.
Contacts:
Media
Amanda Sheldon, head of Corporate Communications
media@arcutis.com
Investors
Brian Schoelkopf, head of Investor Relations
ir@arcutis.com
| ARCUTIS BIOTHERAPEUTICS, INC. Condensed Consolidated Balance Sheets (In thousands) (unaudited) | ||||||||
| September 30, | December 31, | |||||||
| 2026 | 2025 | |||||||
| ASSETS | ||||||||
| Current assets: | ||||||||
| Cash and cash equivalents | $ | 33,373 | $ | 42,907 | ||||
| Restricted cash | 308 | 308 | ||||||
| Marketable securities | 226,087 | 178,075 | ||||||
| Trade receivables, net | 171,281 | 146,229 | ||||||
| Inventory | 45,669 | 22,634 | ||||||
| Prepaid expenses and other current assets | 26,972 | 21,079 | ||||||
| Total current assets | 503,690 | 411,232 | ||||||
| Property and equipment, net | 796 | 1,043 | ||||||
| Intangible assets, net | 13,125 | 14,812 | ||||||
| Operating lease right-of-use asset | 4,145 | 4,467 | ||||||
| Other assets | 2,670 | 1,419 | ||||||
| Total assets | $ | 524,426 | $ | 432,973 | ||||
| LIABILITIES AND STOCKHOLDERS’ EQUITY | ||||||||
| Current liabilities: | ||||||||
| Accounts payable | $ | 8,342 | $ | 12,528 | ||||
| Current portion of long-term debt, net | 6,950 | 1,000 | ||||||
| Accrued and other current liabilities | 157,065 | 116,310 | ||||||
| Total current liabilities | 172,357 | 129,838 | ||||||
| Operating lease liability, noncurrent | 5,224 | 5,266 | ||||||
| Long-term debt, net | 102,448 | 107,959 | ||||||
| Other long-term liabilities | 431 | 431 | ||||||
| Total liabilities | 280,460 | 243,494 | ||||||
| Stockholders’ equity: | ||||||||
| Common stock | 12 | 12 | ||||||
| Additional paid-in capital | 1,370,692 | 1,327,595 | ||||||
| Accumulated other comprehensive loss | (1,169 | ) | (44 | ) | ||||
| Accumulated deficit | (1,125,569 | ) | (1,138,084 | ) | ||||
| Total stockholders’ equity | 243,966 | 189,479 | ||||||
| Total liabilities and stockholders’ equity | $ | 524,426 | $ | 432,973 | ||||
| ARCUTIS BIOTHERAPEUTICS, INC. Condensed Consolidated Statements of Operations (In thousands, except per share data) (unaudited) | ||||||||||||||||
| Three Months Ended September 30, | Nine Months Ended September 30, | |||||||||||||||
| 2026 | 2025 | 2026 | 2025 | |||||||||||||
| Revenues: | ||||||||||||||||
| Product revenue, net | $ | 143,919 | $ | 99,219 | $ | 379,178 | $ | 244,569 | ||||||||
| Other revenue | — | — | — | 2,000 | ||||||||||||
| Total revenues | 143,919 | 99,219 | 379,178 | 246,569 | ||||||||||||
| Operating expenses: | ||||||||||||||||
| Cost of sales | 12,460 | 8,685 | 33,183 | 25,007 | ||||||||||||
| Research and development | 22,422 | 19,604 | 73,404 | 56,600 | ||||||||||||
| Selling, general, and administrative | 99,601 | 62,404 | 255,815 | 195,576 | ||||||||||||
| Total operating expenses | 134,483 | 90,693 | 362,402 | 277,183 | ||||||||||||
| Income (loss) from operations | 9,436 | 8,526 | 16,776 | (30,614 | ) | |||||||||||
| Other income (expense): | ||||||||||||||||
| Interest income | 2,596 | 2,118 | 7,150 | 6,731 | ||||||||||||
| Interest expense | (2,959 | ) | (3,071 | ) | (10,733 | ) | (9,082 | ) | ||||||||
| Other income (expense), net | (77 | ) | (83 | ) | (254 | ) | 130 | |||||||||
| Total other income (expense) | (440 | ) | (1,036 | ) | (3,837 | ) | (2,221 | ) | ||||||||
| Income (loss) before income taxes | 8,996 | 7,490 | 12,939 | (32,835 | ) | |||||||||||
| Provision for income taxes | 195 | 80 | 424 | 701 | ||||||||||||
| Net income (loss) | $ | 8,801 | $ | 7,410 | $ | 12,515 | $ | (33,536 | ) | |||||||
| Earnings (loss) per share: | ||||||||||||||||
| Basic | $ | 0.07 | $ | 0.06 | $ | 0.10 | $ | (0.26 | ) | |||||||
| Diluted | $ | 0.06 | $ | 0.06 | $ | 0.09 | $ | (0.26 | ) | |||||||
| Weighted-average shares used in computing earnings (loss) per share: | ||||||||||||||||
| Basic | 131,011 | 127,623 | 130,306 | 126,891 | ||||||||||||
| Diluted | 136,836 | 132,885 | 136,192 | 126,891 | ||||||||||||
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What were Arcutis ARQT's third-quarter 2026 sales and earnings?
Arcutis reported $143.9 million in net product sales and $8.8 million in net income for the quarter ended September 30, 2026. Sales increased 45% year over year and 11% from the second quarter. Basic earnings per share were $0.07, while diluted earnings per share were $0.06.
What is Arcutis ARQT's updated 2026 sales guidance?
Arcutis raised its full-year 2026 net product sales guidance to $535 million–$545 million, compared with its previous range of $525 million–$540 million.
Why did Arcutis ARQT's selling and administrative expenses increase in Q3 2026?
The increase reflected greater marketing spending and personnel-related expenses. Marketing spending primarily supported the Skin to Believe In celebrity awareness campaign. Personnel expenses increased with the dermatology sales force expansion and the launch of the primary care provider and pediatric sales team.
How much revenue did each Arcutis ZORYVE product generate in Q3 2026?
ZORYVE topical foam 0.3% generated $75.1 million in third-quarter revenue. ZORYVE cream 0.3% generated $37.8 million, cream 0.15% generated $27.3 million, and cream 0.05% generated $3.7 million. All products grew during the quarter.